

Appendix 1.

Bibliography of 31 noninferiority trials (reporting 36 comparisons) that used a reduced intensity therapy as the new therapy compared to the same therapy at full intensity as active control.¹⁻³¹

1. Anderson CS, Robinson T, Lindley RI, et al. Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke. *New England Journal of Medicine* 2016;374(24):2313-23. doi: 10.1056/NEJMoa1515510
2. Radford J, Illidge T, Counsell N, et al. Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin's Lymphoma. *New England Journal of Medicine* 2015;372(17):1598-607. doi: 10.1056/NEJMoa1408648
3. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD. *New England Journal of Medicine* 2014;371(14):1285-94. doi: 10.1056/NEJMoa1407154
4. Paton NI, Kityo C, Hoppe A, et al. Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa. *New England Journal of Medicine* 2014;371(3):234-47. doi: 10.1056/NEJMoa1311274
5. Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S, et al. A Randomized Trial of Prolonged Co-trimoxazole in HIV-Infected Children in Africa. *New England Journal of Medicine* 2014;370(1):41-53. doi: 10.1056/NEJMoa1214901
6. Johnson P, Federico M, Kirkwood A, et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. *New England Journal of Medicine* 2016;374(25):2419-29. doi: 10.1056/NEJMoa1510093
7. Hussain M, Tangen CM, Berry DL, et al. Intermittent versus Continuous Androgen Deprivation in Prostate Cancer. *New England Journal of Medicine* 2013;368(14):1314-25. doi: 10.1056/NEJMoa1212299
8. Crook JM, O'Callaghan CJ, Duncan G, et al. Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy. *New England Journal of Medicine* 2012;367(10):895-903. doi: 10.1056/NEJMoa1201546
9. Mallick U, Harmer C, Yap B, et al. Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer. *New England Journal of Medicine* 2012;366(18):1674-85. doi: 10.1056/NEJMoa1109589
10. Kim K, Kim YH, Kim SY, et al. Low-Dose Abdominal CT for Evaluating Suspected Appendicitis. *New England Journal of Medicine* 2012;366(17):1596-605. doi: 10.1056/NEJMoa1110734
11. Sherman KE, Flamm SL, Afdhal NH, et al. Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection. *New England Journal of Medicine* 2011;365(11):1014-24. doi: 10.1056/NEJMoa1014463
12. Rahman NM, Pepperell J, Rehal S, et al. Effect of opioids vs nsoids and larger vs smaller chest tube size on pain control and pleurodesis efficacy among patients with malignant pleural effusion: The time1 randomized clinical trial. *JAMA* 2015;314(24):2641-53. doi: 10.1001/jama.2015.16840
13. Feres F, Costa RA, Abizaid A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: The optimize randomized trial. *JAMA* 2013;310(23):2510-22. doi: 10.1001/jama.2013.282183
14. Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: The reduce randomized clinical trial. *JAMA* 2013;309(21):2223-31. doi: 10.1001/jama.2013.5023

15. Strnad V, Ott OJ, Hildebrandt G, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. *The Lancet* 2016;387(10015):229-38. doi: [https://doi.org/10.1016/S0140-6736\(15\)00471-7](https://doi.org/10.1016/S0140-6736(15)00471-7)
16. Pritchard-Jones K, Bergeron C, de Camargo B, et al. Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. *The Lancet* 2015;386(9999):1156-64. doi: [https://doi.org/10.1016/S0140-6736\(14\)62395-3](https://doi.org/10.1016/S0140-6736(14)62395-3)
17. Barone MA, Widmer M, Arrowsmith S, et al. Breakdown of simple female genital fistula repair after 7 day versus 14 day postoperative bladder catheterisation: a randomised, controlled, open-label, non-inferiority trial. *The Lancet* 2015;386(9988):56-62. doi: [https://doi.org/10.1016/S0140-6736\(14\)62337-0](https://doi.org/10.1016/S0140-6736(14)62337-0)
18. Behringer K, Goergen H, Hitz F, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. *The Lancet* 2015;385(9976):1418-27. doi: [https://doi.org/10.1016/S0140-6736\(14\)61469-0](https://doi.org/10.1016/S0140-6736(14)61469-0)
19. Bernard L, Dinh A, Ghout I, et al. Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial. *The Lancet* 2015;385(9971):875-82. doi: [https://doi.org/10.1016/S0140-6736\(14\)61233-2](https://doi.org/10.1016/S0140-6736(14)61233-2)
20. Vain NE, Satragno DS, Gorenstein AN, et al. Effect of gravity on volume of placental transfusion: a multicentre, randomised, non-inferiority trial. *The Lancet* 2014;384(9939):235-40. doi: [https://doi.org/10.1016/S0140-6736\(14\)60197-5](https://doi.org/10.1016/S0140-6736(14)60197-5)
21. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naïve adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. *The Lancet* 2014;383(9927):1474-82. doi: [https://doi.org/10.1016/S0140-6736\(13\)62187-X](https://doi.org/10.1016/S0140-6736(13)62187-X)
22. Herpertz-Dahlmann B, Schwarte R, Krei M, et al. Day-patient treatment after short inpatient care versus continued inpatient treatment in adolescents with anorexia nervosa (ANDI): a multicentre, randomised, open-label, non-inferiority trial. *The Lancet* 2014;383(9924):1222-29. doi: [https://doi.org/10.1016/S0140-6736\(13\)62411-3](https://doi.org/10.1016/S0140-6736(13)62411-3)
23. Chetchotisakd P, Chierakul W, Chaowagul W, et al. Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradication treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial. *The Lancet* 2014;383(9919):807-14. doi: [https://doi.org/10.1016/S0140-6736\(13\)61951-0](https://doi.org/10.1016/S0140-6736(13)61951-0)
24. Sandberg T, Skoog G, Hermansson AB, et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. *The Lancet* 2012;380(9840):484-90. doi: [https://doi.org/10.1016/S0140-6736\(12\)60608-4](https://doi.org/10.1016/S0140-6736(12)60608-4)
25. Kirchhof P, Andresen D, Bosch R, et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. *The Lancet* 2012;380(9838):238-46. doi: [https://doi.org/10.1016/S0140-6736\(12\)60570-4](https://doi.org/10.1016/S0140-6736(12)60570-4)
26. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. *The Lancet* 2012;379(9828):1791-99. doi: [https://doi.org/10.1016/S0140-6736\(11\)61940-5](https://doi.org/10.1016/S0140-6736(11)61940-5)

27. Gülmezoglu AM, Lumbiganon P, Landoulsi S, et al. Active management of the third stage of labour with and without controlled cord traction: a randomised, controlled, non-inferiority trial. *The Lancet* 2012;379(9827):1721-27. doi: [https://doi.org/10.1016/S0140-6736\(12\)60206-2](https://doi.org/10.1016/S0140-6736(12)60206-2)
28. Tashima KT, Smeaton LM, Fichtenbaum CJ, et al. Hiv salvage therapy does not require nucleoside reverse transcriptase inhibitors: A randomized, controlled trial. *Annals of Internal Medicine* 2015;163(12):908-17. doi: 10.7326/M15-0949
29. Schulman S, Parpia S, Stewart C, et al. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: A randomized trial. *Annals of Internal Medicine* 2011;155(10):653-59. doi: 10.7326/0003-4819-155-10-201111150-00003
30. Mol GC, van de Ree MA, Klok FA, et al. One versus two years of elastic compression stockings for prevention of post-thrombotic syndrome (OCTAVIA study): randomised controlled trial. *BMJ* 2016;353 doi: 10.1136/bmj.i2691
31. van Herwaarden N, van der Maas A, Minten MJM, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. *BMJ : British Medical Journal* 2015;350 doi: 10.1136/bmj.h1389